13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001920938
Total reported value
$2.7B
$2.7B
64 檔
25.6%
The Q1 2025 SEC filing reveals that Braidwell LP held a total portfolio value of $2.7B, covering 64 public equity positions.
In Q1 2025, Braidwell LP adopted a defensive or profit-taking posture, trimming 20 positions and completely liquidating 22 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including GH 1.25 02-15-31, NVCR 0 11-01-25, NBIX) accounted for 25.6% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GH 1.25 02-15-31Bond | Guardant Health Inc | Bond | 7.99% | -3.42% | EXIT | |
| 2 | NVCR 0 11-01-25Bond | Novocure LTD | Bond | 4.80% | — | — | |
| 3 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 4.63% | -0.77% | +32.17% | |
| 4 | LEGN | Legend Biotech Corp-adr | Stock-Other | 3.55% | — | — | |
| 5 | RGEN 1 12-15-28Bond | Repligen CORP | Bond | 3.37% | -2.68% | -12.50% | |
| 6 | ARGX | Argenx Se - Adr | Stock-Healthcare | 3.35% | -1.46% | +99.15% | |
| 7 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.20% | -0.07% | -7.00% | |
| 8 | IRTC 1.5 09-01-29Bond | Irhythm Holdings Inc | Bond | 3.15% | — | — | |
| 9 | NEO 0.25 01-15-28Bond | Neogenomics Inc | Bond | 3.09% | -2.44% | -12.89% | |
| 10 | ALGN | Align Technology Inc | Stock-Healthcare | 2.96% | — | +41.41% | |
| 11 | IRWD 1.5 06-15-26Bond | Ironwood Pharmaceuticals | Bond | 2.90% | — | — | |
| 12 | CGON | Cg Oncology Inc | Stock-Other | 2.83% | -2.22% | EXIT | |
| 13 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 2.54% | +0.20% | +99.87% | |
| 14 | BBIO 2.5 03-15-27Bond | Bridgebio Pharma Inc | Bond | 2.53% | — | -55.38% | |
| 15 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 2.23% | +0.14% | +42.31% | |
| 16 | DHR | Danaher CORP | Stock-Healthcare | 2.23% | +0.18% | — | |
| 17 | GKOS | Glaukos CORP | Stock-Healthcare | 2.16% | +0.32% | +116.16% | |
| 18 | NUVL | Nuvalent Inc-a | Stock-Other | 2.10% | -2.39% | EXIT | |
| 19 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 2.05% | +0.48% | -21.12% | |
| 20 | APGE | Apogee Therapeutics Inc | Stock-Other | 2.02% | -1.34% | EXIT | |
| 21 | TMDX | Transmedics Group Inc | Stock-Healthcare | 2.02% | +0.41% | -7.29% | |
| 22 | GH | Guardant Health Inc | Stock-Healthcare | 1.99% | -0.72% | -53.39% | |
| 23 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.90% | +0.53% | +5.43% | |
| 24 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 1.69% | -0.05% | +3.07% | |
| 25 | BBIO 2.25 02-01-29Bond | Bridgebio Pharma Inc | Bond | 1.54% | — | -9.33% | |
| 26 | IMCR 2.5 02-01-30Bond | Immunocore Holdings | Bond | 1.54% | — | — | |
| 27 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 1.53% | -0.01% | -43.14% | |
| 28 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.53% | -0.16% | +16.87% | |
| 29 | ATEC | Alphatec Holdings Inc | Stock-Other | 1.52% | +1.30% | +0.07% | |
| 30 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.46% | +1.32% | — | |
| 31 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.37% | — | — | |
| 32 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.33% | -0.26% | +431.63% | |
| 33 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.27% | — | -21.27% | |
| 34 | ADPT | Adaptive Biotechnologies | Stock-Other | 1.25% | — | — | |
| 35 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.22% | — | -2.95% | |
| 36 | PEN | Penumbra Inc | Stock-Healthcare | 1.04% | -1.15% | EXIT | |
| 37 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.99% | — | +8.10% | |
| 38 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.99% | — | -27.43% | |
| 39 | KIDS | Orthopediatrics CORP | Stock-Other | 0.96% | +0.20% | — | |
| 40 | HROW | Harrow Inc | Stock-Other | 0.89% | -0.18% | EXIT | |
| 41 | DXCM 0.375 05-15-28Bond | Dexcom Inc | Bond | 0.80% | — | -69.23% | |
| 42 | MRVI | Maravai Lifesciences Hldgs-a | Stock-Other | 0.65% | +1.04% | — | |
| 43 | DXCM 0.25 11-15-25Bond | Dexcom Inc | Bond | 0.63% | — | — | |
| 44 | XNCR | Xencor Inc | Stock-Other | 0.62% | — | +168.99% | |
| 45 | ASND | Ascendis Pharma A/S | Stock-Other | 0.58% | — | — | |
| 46 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.57% | +0.98% | NEW | |
| 47 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.57% | — | — | |
| 48 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.53% | — | -35.74% | |
| 49 | REPL | Replimune Group Inc | Stock-Other | 0.50% | — | -1.03% | |
| 50 | RGEN | Repligen CORP | Stock-Healthcare | 0.37% | +0.70% | -71.23% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GH 1.25 02-15-31Bond | Guardant Health Inc | +8% | NEW | New buy |
| 2 | IRTC 1.5 09-01-29Bond | Irhythm Holdings Inc | +3.2% | NEW | New buy |
| 3 | DHR | Danaher CORP | +2.2% | NEW | New buy |
| 4 | ARGX | Argenx Se - Adr | +1.9% | +99.15% | Add |
| 5 | KRYS | Krystal Biotech Inc | +1.6% | +99.87% | Add |
| 6 | IMCR 2.5 02-01-30Bond | Immunocore Holdings | +1.5% | NEW | New buy |
| 7 | NUVL | Nuvalent Inc-a | +1.5% | +248.60% | Add |
| 8 | 2655787D | Blueprint Medicines CORP | +1.4% | NEW | New buy |
| 9 | ADPT | Adaptive Biotechnologies | +1.3% | NEW | New buy |
| 10 | NBIX | Neurocrine Biosciences Inc | +1% | +32.17% | Add |
| 11 | GKOS | Glaukos CORP | +0.9% | +116.16% | Add |
| 12 | DYN | Dyne Therapeutics Inc | +0.9% | +431.63% | Add |
| 13 | TMO | Thermo Fisher Scientific Inc | +0.9% | +42.31% | Add |
| 14 | NVCR 0 11-01-25Bond | Novocure LTD | +0.8% | — | Unchanged |
| 15 | LEGN | Legend Biotech Corp-adr | +0.7% | — | Unchanged |
| 16 | ALGN | Align Technology Inc | +0.6% | +41.41% | Add |
| 17 | ASND | Ascendis Pharma A/S | +0.6% | NEW | New buy |
| 18 | MDGL | Madrigal Pharmaceuticals Inc | +0.6% | NEW | New buy |
| 19 | IRWD 1.5 06-15-26Bond | Ironwood Pharmaceuticals | +0.4% | — | Unchanged |
| 20 | ISRG | Intuitive Surgical Inc | +0.4% | +16.87% | Add |
| 21 | ATEC | Alphatec Holdings Inc | +0.4% | +0.07% | Add |
| 22 | TMDX | Transmedics Group Inc | +0.3% | -7.29% | Trim |
| 23 | CSTL | Castle Biosciences Inc | +0.3% | NEW | New buy |
| 24 | XNCR | Xencor Inc | +0.2% | +168.99% | Add |
| 25 | KIDS | Orthopediatrics CORP | +0.2% | — | Unchanged |
| 26 | NEO 0.25 01-15-28Bond | Neogenomics Inc | +0.2% | -12.89% | Trim |
| 27 | BBIO 2.25 02-01-29Bond | Bridgebio Pharma Inc | +0.2% | -9.33% | Trim |
| 28 | ✓ | +0.2% | NEW | New buy | |
| 29 | IRTC | Irhythm Holdings Inc | +0.2% | -21.12% | Trim |
| 30 | AARD | Aardvark Therapeutics Inc | +0.1% | NEW | New buy |
| 31 | DXCM 0.25 11-15-25Bond | Dexcom Inc | +0.1% | — | Unchanged |
| 32 | INSP | Inspire Medical Systems Inc | +0.1% | +3.07% | Add |
| 33 | BBNX | Beta Bionics Inc | +0.1% | NEW | New buy |
| 34 | EWTX | Edgewise Therapeutics Inc | +0.1% | +5.43% | Add |
| 35 | CGON | Cg Oncology Inc | 0% | — | Unchanged |
| 36 | LUNG | Pulmonx CORP | 0% | — | Unchanged |
| 37 | TRVI | Trevi Therapeutics Inc | 0% | NEW | New buy |
| 38 | ✓ | 0% | — | Unchanged | |
| 39 | HROW | Harrow Inc | 0% | +5.49% | Add |
| 40 | SKYE | Skye Bioscience Inc | 0% | — | Unchanged |
| 41 | PTGX | Protagonist Therapeutics Inc | 0% | EXIT | Sold out |
| 42 | VRDN | Viridian Therapeutics Inc | 0% | EXIT | Sold out |
| 43 | RGEN 1 12-15-28Bond | Repligen CORP | 0% | -12.50% | Trim |
| 44 | REPL | Replimune Group Inc | 0% | -1.03% | Trim |
| 45 | CELC | Celcuity Inc | 0% | — | Unchanged |
| 46 | BCAX | Bicara Therapeutics Inc | 0% | +8.10% | Add |
| 47 | APGE | Apogee Therapeutics Inc | -0.1% | — | Unchanged |
| 48 | ✓ | Zura Bio LTD | -0.1% | — | Unchanged |
| 49 | CUTR 2.25 06-01-28Bond | Cutera Inc | -0.1% | EXIT | Sold out |
| 50 | CUTR 4 06-01-29Bond | Cutera Inc | -0.1% | EXIT | Sold out |
According to official SEC Form 13F filings, Braidwell LP reported a total U.S. public equity portfolio value of $2.7B across 64 disclosed positions in Q1 2025.
During Q1 2025, Braidwell LP's top holdings by market value included GH 1.25 02-15-31 (8.0%)、NVCR 0 11-01-25 (4.8%)、NBIX (4.6%). The largest single position, GH 1.25 02-15-31, represented 8.0% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
GH 1.25 02-15-31
市值: $227.4M
Top Position Liquidated / Trimmed
GH 0 11-15-27
前期市值: $226.0M
In Q1 2025, Braidwell LP made 72 total portfolio adjustments, initiating 13 new buys, adding to 17 positions, trimming 20 holdings, and fully liquidating 22 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.